Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING

IMplementation of CAB+RPV LA for People With HIV in Non-Metropolitan Areas

NCT06451341 · View on ClinicalTrials.gov ↗

Study Summary

The goal of this implementation science study is to learn about the experience of receiving and providing cabotegravir + rilpivirine long-acting (CAB+RPV LA) injections as treatment for human immunodeficiency virus (HIV) for people who live a significant distance from an HIV provider. The main questions it aims to answer are: * Is CAB+RPV LA feasible and acceptable to patients and staff? * What barriers and supports exist and have the most impact on receiving and providing CAB+RPV LA? * How does CAB+RPV LA affect HIV stigma, treatment satisfaction, medication adherence and viral suppression? People living with HIV who reside outside of the Omaha, Nebraska metro area and are starting CAB+RPV LA as part of regular medical care for HIV will be invited to participate in this study which involves completing questionnaires and an interview over 15 months. Clinic staff who are involved in providing HIV care and CAB+RPV LA will also provide input through questionnaires and an interview.

Conditions Studied

Interventions

  • BEHAVIORAL Acceptability of Intervention Measure (AIM)
  • BEHAVIORAL Intervention Appropriateness Measure (IAM)
  • BEHAVIORAL Feasibility of Intervention Measure (FIM)
  • BEHAVIORAL HIV Stigma Scale Questionnaire
  • BEHAVIORAL HIV Treatment Satisfaction Questionnaire status version (HIVTSQs12)

Study Locations (2)

Nebraska

  • Nebraska Medicine Grand Island Clinic — Grand Island
  • University of Nebraska Specialty Care Center — Omaha

Trial Details

FieldValue
Enrollment Target 55 participants
Start Date 2024-07-01
Est. Completion 2027-04

Sponsor

University of Nebraska

272 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06451341

The ClinicalTrials.gov registry entry for NCT06451341 describes a study currently listed as recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Nebraska, which has 272 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with HIV appearing as the primary indexed condition, and to 5 interventions — of which Acceptability of Intervention Measure (AIM) is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT06451341 reports 2 study locations spanning 1 distinct geographic area — top geographies include Nebraska. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT06451341 about?

NCT06451341 is a clinical study titled "IMplementation of CAB+RPV LA for People With HIV in Non-Metropolitan Areas". The goal of this implementation science study is to learn about the experience of receiving and providing cabotegravir + rilpivirine long-acting (CAB+RPV LA) injections as treatment for human immunodeficiency virus (HIV) for people who live a significant distance from an HIV provider. The main quest...

What is the current status of trial NCT06451341?

This trial is currently recruiting. The enrollment target is 55 participants. The study started on 2024-07-01. Estimated completion is 2027-04.

What conditions does trial NCT06451341 study?

This clinical trial studies the following conditions: HIV. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT06451341?

The interventions under investigation include: Acceptability of Intervention Measure (AIM) (BEHAVIORAL), Intervention Appropriateness Measure (IAM) (BEHAVIORAL), Feasibility of Intervention Measure (FIM) (BEHAVIORAL), HIV Stigma Scale Questionnaire (BEHAVIORAL), HIV Treatment Satisfaction Questionnaire status version (HIVTSQs12) (BEHAVIORAL). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT06451341?

This trial is sponsored by University of Nebraska, which has 272 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT06451341 being conducted?

This trial has 2 study locations across Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial